Titre:
  • Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Auteur:Kelley, Robin Kate; Rimassa, Lorenza; Cheng, Ann Lii; Kaseb, Ahmed; Qin, Shukui; Zhu, Andrew Xiuxuan; Chan, Stephen Lam; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Banerjee, Kamalika; Hazra, Saswati; Fawcett, Jonathan; Yau, Thomas
Informations sur la publication:Lancet oncology, 23, 8, page (995-1008)
Statut de publication:Publié, 2022-08
Sujet CREF:Cancérologie
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(22)00326-6
info:pii/S1470204522003266
info:scp/85134753909
info:pmid/35798016